Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
N/A for expanded access
Drug: Selpercatinib
Open-label expanded access
Other Name: Array
Inclusion Criteria:
- Diagnosis of cancer with RET activation, who are not eligible for an ongoing
selpercatinib clinical trial and are medically suitable for treatment with
selpercatinib
- Have progressed or are intolerant to standard therapy, or no standard therapy option
exists, or in the opinion of the investigator, are unlikely to derive significant
clinical benefit from standard therapy
- Have adequate organ function
Exclusion Criteria:
- Currently enrolled in an ongoing clinical study of selpercatinib or another RET
inhibitor
- Clinically significant active cardiovascular disease or history of myocardial
infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or
current prolongation of the QT interval corrected for heart rate using Fridericia's
formula (QTcF) interval greater than 470 milliseconds
Cancer Treatment Centers of America
Goodyear, Arizona, United States
Mayo Clinic of Scottsdale
Scottsdale, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
Irvine Medical Center
Orange, California, United States
University of California - San Diego
San Diego, California, United States
Univ of California San Francisco
San Francisco, California, United States
Memorial Cancer Institute
Hollywood, Florida, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Florida Hospital
Orlando, Florida, United States
Tallahassee Memorial Cancer Center
Tallahassee, Florida, United States
University Cancer and Blood Center
Athens, Georgia, United States
Emory University
Atlanta, Georgia, United States
University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois, United States
Cancer Treatment Centers of America
Zion, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
START Midwest
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Cancer Treatment Centers of America
Tulsa, Oklahoma, United States
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Eastern Regional Medical Center
Philadelphia, Pennsylvania, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin, United States
NSW Health - Sydney Local Health District
Camperdown, New South Wales, Australia
Royal North Shore Hospital
St. Leonards, New South Wales, Australia
Queensland Health - Metro North Hospital and Health Service
Chermside, Queensland, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, Aquitaine, France
AP-HM
Marseille, France
Universitätsklinikum Würzburg A. ö. R.
Würzburg, Bayern, Germany
Universitätsklinikum Köln
Köln, Nordrhein-Westfalen, Germany
Charité Campus Virchow-Klinikum
Berlin, Germany
Shaare Zedek Medical Center
Jerusalem, Yerushalayim, Israel
Soroka Medical Center - Pediatric Outpatient Clinic
Beer-Sheva, Israel
Istituto Nazionale dei Tumori
Milano, Lombardie, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, PI, Italy
ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C
Milano, Italy
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Tottori University Hospital
Yonago, Tottori, Japan
Osaka City General Hospital
Osaka, Japan
University of Auckland
Auckland, New Zealand
Centrum Onkologii Instytut im Marii Curie w Warszawie
Warszawa, Poland
National Cancer Centre Singapore
Singapore, Central Singapore, Singapore
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Hospital Madrid Norte Sanchinarro
Madrid, Spain
Kantonsspital Luzern
Luzern 16, Luzern, Switzerland
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
ClinicalTrials.gov@lilly.com
Contact Lilly at 1-800-LillyRx (1-800-545-5979), Study Director
Eli Lilly and Company